AbCellera Biologics Inc. (NASDAQ:ABCL) Major Shareholder Holdings Ltd. Thermopylae Sells 5,598,420 Shares

AbCellera Biologics Inc. (NASDAQ:ABCL) major shareholder Holdings Ltd. Thermopylae sold 5,598,420 shares of AbCellera Biologics stock in a transaction dated Wednesday, June 9th. The stock was sold at an average price of $24.03, for a total value of $134,530,032.60. Following the sale, the insider now directly owns 55,604,330 shares in the company, valued at $1,336,172,049.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of NASDAQ:ABCL opened at $24.84 on Friday. The company has a market cap of $6.73 billion and a price-to-earnings ratio of 55.20. AbCellera Biologics Inc. has a 12 month low of $23.20 and a 12 month high of $71.91. The stock’s 50-day moving average is $28.99.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings results on Wednesday, May 12th. The company reported $0.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.37. The firm had revenue of $202.74 million for the quarter, compared to analyst estimates of $199.43 million. On average, analysts predict that AbCellera Biologics Inc. will post 0.44 earnings per share for the current fiscal year.

Several equities analysts have commented on the company. Berenberg Bank reaffirmed a “buy” rating and issued a $53.00 price target on shares of AbCellera Biologics in a report on Tuesday, March 30th. Stifel Nicolaus reduced their target price on AbCellera Biologics from $59.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, March 30th. Zacks Investment Research downgraded shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Friday, April 2nd. BMO Capital Markets decreased their target price on shares of AbCellera Biologics from $61.00 to $59.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 24th. Finally, Credit Suisse Group dropped their price target on shares of AbCellera Biologics from $53.00 to $51.00 and set an “outperform” rating for the company in a research report on Friday, May 14th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. AbCellera Biologics currently has a consensus rating of “Buy” and an average target price of $52.60.

Hedge funds and other institutional investors have recently modified their holdings of the company. Evoke Wealth LLC acquired a new stake in shares of AbCellera Biologics during the 1st quarter worth approximately $27,000. Lumina Fund Management LLC acquired a new stake in AbCellera Biologics during the 1st quarter worth $102,000. UBS Group AG raised its position in shares of AbCellera Biologics by 38,262.5% during the 1st quarter. UBS Group AG now owns 3,069 shares of the company’s stock valued at $104,000 after acquiring an additional 3,061 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new stake in AbCellera Biologics in the fourth quarter valued at about $212,000. Finally, Geode Capital Management LLC grew its position in shares of AbCellera Biologics by 2.9% during the 1st quarter. Geode Capital Management LLC now owns 195,537 shares of the company’s stock worth $6,640,000 after buying an additional 5,431 shares during the period. 26.09% of the stock is currently owned by institutional investors.

AbCellera Biologics Company Profile

AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract.

Featured Article: Cost of Capital Explained

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.